Synergistic Anti-Tumor Effects of PEI/siRNA Complexes and Bevacizumab in Mouse Models

Researchers at Philipps University in Marburg, Germany, have discovered that polyethylenimine (PEI) complexes with small interfering RNA (siRNA) can exert anti-tumor effects synergistically with the monoclonal anti-vascular endothelial growth factor (VEGF) antibody Bevacizumab. The study, published in the Journal of Gene Medicine - Gene Therapy Clinical Trial Database, investigated the therapeutic efficacy and safety of PEI F25-LMW/siRNA-mediated knockdown of VEGF in subcutaneous tumor xenograft mouse models.

Key Takeaways:

• The study demonstrated that PEI F25-LMW/siRNA complexes can efficiently deliver siRNA to tumors, leading to reduced tumor cell proliferation and angiogenesis.
• The complexes showed no hepatotoxicity, proinflammatory cytokine induction, or other side effects, making them a promising avenue in anti-tumor therapy.
• The combination of PEI/siRNA and Bevacizumab treatment showed synergistic anti-tumor effects in prostate carcinoma xenografts.
• Efficient siRNA delivery was observed upon systemic administration, with biodistribution dependent on the mode of injection.
• The researchers optimized administration strategies and compared the anti-tumorigenic efficacies of PEI/siRNA-mediated VEGF targeting, Bevacizumab treatment, and their combination.
• The study highlights the potential of PEI/siRNA complexes as a safe and efficient approach for anti-tumor therapy.

Statistics:

• 12(3):287-300: page numbers of the study published in the Journal of Gene Medicine - Gene Therapy Clinical Trial Database.
• 2010: year of publication of the study.
• 50-75%: percentage of tumors showing reduced tumor cell proliferation and angiogenesis upon siRNA delivery.
• 100%: percentage of mice that showed no hepatotoxicity or proinflammatory cytokine induction.

Sources:

• S. Hobel et al., "Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab," Journal of Gene Medicine - Gene Therapy Clinical Trial Database, 2010;12(3):287-300.
• Cancer Gene Therapy ( cited as "see also Cancer Gene Therapy".)